SAVA Healthcare to set up second manufacturing plant in Indore

SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March.

SAVA Healthcare currently operates a Health Canada, PIC/s approved facility in Gujarat’s Surendranagar and an R&D centre in Pune.

The proposed second plant will have a projected annual production capacity of 2,351.3 million SKUs which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays, and dry powders for inhalation.

Situated on 13.8 acres of prime land, the forthcoming facility will reportedly meet stringent regulatory standards such as EUGMP / USFDA of global pharma markets.

SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March.

This green field project will expand the manufacturing capabilities of SAVA Healthcare as well as create 1000+ job opportunities, offering advanced skill development for the local talent pool.

SAVA Healthcare currently operates a Health Canada, PIC/s approved facility in Gujarat’s Surendranagar and an R&D centre in Pune.

The proposed second plant will have a projected annual production capacity of 2,351.3 million SKUs which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays, and dry powders for inhalation.

Speaking about the new manufacturing plant, Vinod Jadhav, Chairman, SAVA Healthcare , said, “We are thrilled to commence this facility as it marks the initiation of a transformative phase in our journey. We want to emerge as a key player in the global contract manufacturing landscape and by expanding our manufacturing capabilities, we not only achieve that but also elevate Indore’s position in the pharmaceutical landscape.”

Situated on 13.8 acres of prime land, the forthcoming facility will reportedly meet stringent regulatory standards such as EUGMP / USFDA of global pharma markets. The construction of the facility is slated to be executed in two planned phases. The first phase with a built-up area of 29,000 square meters is targeted for completion within a year, while the second phase will be completed by 2026.

“The new manufacturing facility will cater to the growing demand for quality pharmaceuticals in India and globally. Through this expansion, we will additionally create meaningful opportunities for the people in the region,” said Dinesh Kapoor, Managing Director, SAVA Healthcare.

SAVA Healthcare exports pharma products to more than 35 countries including Canada, Ukraine, the CIS, Asia, and Africa (especially FWA – French West Africa). Reportedly known for its expertise in Nasal Drug Delivery Platforms, SAVA’s CRAMS division caters to a diverse clientele of Indian and international companies.